Table 3 The relationship between SGEF expression and clinicopathological features of LAC patients
From: SGEF is a potential prognostic and therapeutic target for lung adenocarcinoma
| Â | SGEF | Â | |
|---|---|---|---|
Feature | High (n = 54) | Low (n = 38) | P value |
Gender |  |  | P = 0.192 |
 Male | 33 (61.11%) | 18 (47.37%) |  |
 Female | 21 (28.89%) | 20 (52.63%) |  |
Age at diagnosis |  |  | P = 0.781 |
 <60 | 20 (37.04%) | 13 (34.21%) |  |
 ≥ 60 | 34 (62.96%) | 25 (65.79%) |  |
Location |  |  | P = 0.407 |
 Left | 21 (38.89%) | 12 (31.58%) |  |
 Right | 33 (61.11%) | 26 (68.42%) |  |
EGFR status |  |  | P = 0.545 |
 Mutant | 18 (33.33%) | 15 (39.47%) |  |
 Wild type | 36 (66.67%) | 23 (60.53%) |  |
T stage |  |  | P = 0.028 |
 T1–2 | 36 (66.66%) | 33 (86.84%) |  |
 T3–4 | 18 (33.34%) | 5 (13.16%) |  |
N stage |  |  | P = 0.011 |
 N0 | 21 (38.88%) | 25 (65.79%) |  |
 N1–3 | 33 (61.12%) | 13 (34.21%) |  |
TNM stage |  |  | P < 0.001 |
 I | 7 (12.96%) | 18 (47.36%) |  |
 II + III | 47 (87.04%) | 20 (52.63%) |  |
Histological grade |  |  | P = 0.608 |
 Well | 6 (11.11%) | 5 (11.36%) |  |
 Moderate | 42 (77.78%) | 31 (70.45%) |  |
 Poor | 6 (11.11%) | 2 (4.54%) |  |